Skip to main content

Table 2 Best response by RECIST 1.1

From: Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Response

No. of patients (%)

Confirmed CR

0 (0)

Confirmed PR

0 (0)

SD ≥ 4 months§

6 (12)

SD < 4 months

11 (22)

Progressive disease

20 (40)

Non-evaluable*

13 (26)

  1. CR complete response, PR partial response, SD stable disease
  2. §One patient had an unconfirmed PR
  3. *12 patients discontinued treatment before first post-baseline assessment due to clinical progression. One patient discontinued treatment before the first post-baseline assessment due to unacceptable toxicity
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us